# TST003

Source: https://onco.cc/drugs/tst003/  
OnCo record `tst003` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TST003 is a monoclonal antibody from Transcenta Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for colorectal cancer.

## Summary

TST003 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Transcenta Therapeutics (Hangzhou) Co., Ltd., in colorectal cancer. A monoclonal antibody, as described in the registry record. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: TST003
- Modality: Monoclonal antibody
- Mechanism: A monoclonal antibody, as described in the registry record.

## Sources

- ClinicalTrials.gov: trials of TST003: https://clinicaltrials.gov/search?intr=TST003

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- trials: [A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors](https://onco.cc/trials/nct05731271/)

---
JSON: https://onco.cc/api/v1/entities/tst003.json